Is DSIP Peptide Worth Trying?

What is DSIP?

DSIP, short for Delta Sleep-Inducing Peptide, is a naturally occurring nonapeptide, a chain of nine amino acids, with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE). It has a molecular weight of roughly 848 g/mol and is registered under CAS number 62568-57-4. In compounding pharmacy contexts, it also goes by the name Emideltide.

It was first isolated in 1977 from the cerebral venous blood of rabbits during electrically-induced slow-wave sleep, which is how it earned its name.

Since then it has circulated in two very different worlds: as a subject of decades of academic sleep-science research, and, more recently, as a “research peptide” or compounded product marketed for sleep support.

Why its pharmacology gets attention

DSIP behaves unusually for a peptide. It appears to cross the blood-brain barrier freely and is absorbed intact from the gut without being broken down by digestive enzymes, something most peptides cannot do.

At the same time, it is cleared from plasma extremely fast, with a half-life of only 7 to 8 minutes, broken down by enzymes called aminopeptidases.

That combination, easy access to the brain paired with near-instant clearance from the blood, is part of what has kept researchers curious about it for so long, even though, as covered later, it also creates an unresolved puzzle about how a substance gone from the bloodstream in minutes could influence sleep hours or nights later.

What the evidence base actually looks like

Marketing language around DSIP, terms like “deep sleep peptide” or “delta wave booster,” tends to outpace what the human research actually shows. The compound has a long history of animal and mechanistic study going back to the 1970s, but human trials are few and small.

The most frequently cited is a 1992 double-blind trial involving just 16 people with chronic insomnia. That is the extent of the direct human evidence base this article works from: not a body of confirmatory clinical trials, but a handful of small, dated studies with mixed results.

The sections that follow rate DSIP’s evidence honestly by use case rather than treating decades of study as proof that it works.

What the research shows

No use case here reaches Moderate. The strongest human data point is still the single 1992 trial already discussed, and everything below it is thinner still.

Sleep quality & insomnia, Limited

The Bes et al. trial remains the only controlled human study of DSIP for insomnia, and its own authors concluded short-term treatment was unlikely to offer major therapeutic benefit. That “weak, possibly confounded” verdict is the ceiling for this use case, not a footnote to it.

Circadian rhythm regulation, Emerging

DSIP’s plasma levels rise and fall across the day, running low in the morning and higher in the afternoon. That’s a correlational, observed pattern, not evidence that dosing DSIP realigns a disrupted circadian rhythm. No interventional trial has tested it for jet lag, shift work, or delayed sleep phase. Epitalon and circadian peptides

Stress response, cortisol & hormonal effects, including testosterone, Emerging

This is where the evidence base is thinnest relative to how it’s marketed. No study in the record shows DSIP raises testosterone, and one human volunteer study found it had no effect on growth hormone or prolactin at all.

Cortisol and ACTH data actively conflict: one study reported suppressed secretion, another found no change even at large IV doses. Taken together, hormonal regulation by DSIP is not well established, and there is no human data supporting a testosterone benefit specifically.

Pain and inflammation, Emerging

Animal studies describe an antinociceptive effect reversible with naloxone, reduced brain edema, and a neuroprotective effect after carotid ligation. These are rodent findings only; no human pain or inflammation trial has been run.

Neuroprotective & anticonvulsant effects, Emerging

In rodents, DSIP raised the seizure threshold against NMDA and picrotoxin challenge, and separate animal work reported antihypertensive and antimetastatic activity. None of this has been tested or replicated in humans, so it sits alongside the pain data as preclinical only.

Withdrawal symptom relief, alcohol/opioid, Emerging

DSIP has a documented history of clinical exploration for easing alcohol and opioid withdrawal, but the supporting material is thin, dated, and largely observational rather than the product of rigorous controlled trials.

Across all six use cases, the pattern repeats: animal or observational data exist, but rigorous human trials do not, and no claim here should be read as clinically established.

Why Did DSIP Research Stall?

A real scientific disagreement, not a settled verdict

The thinness of DSIP’s evidence base isn’t just a funding gap story, it reflects genuine disagreement among the researchers who studied it. Alexander Borbély, at the University of Zürich, called DSIP “a flop” as a sleep substance, arguing its effects never held up to scrutiny.

Guido Schoenenberger, the Basel researcher who co-discovered DSIP, maintained the opposite: that the original data were conclusive and that research stalled only because funding dried up, not because the science failed. Both positions come from credentialed scientists close to the original work, and no later consensus resolved the dispute.

A peptide without a known lock to fit

Compounding the disagreement is something structurally unusual: decades after isolation, no receptor and no precursor peptide for DSIP has ever been identified. For a compound this extensively studied, that absence is notable, it means researchers have documented effects without ever pinning down how or where DSIP acts.

The bacterial-origin wrinkle

Adding to the uncertainty, BLAST sequence alignment work has flagged similarity between DSIP and sequences from bacteria, including Amycolatopsis coloradensis and other bacterial pseudogenes.

This has led some researchers to float the possibility that DSIP, like the related sleep-promoting substance Factor S, may not be an endogenous mammalian peptide in the way originally assumed, but something closer to a bacterial artifact or contaminant picked up in early isolation methods.

None of this is settled. It’s an open, unresolved thread in a compound’s history, worth understanding before weighing any claims about what DSIP does.

The Half-Life Paradox: Why Timing and Duration Don't Match

On paper, DSIP’s pharmacokinetics don’t match its reported effects. Plasma half-life is 7 to 8 minutes, cleared quickly by aminopeptidases. Yet in research protocols, doses given during the day were associated with improved sleep that night, and sometimes for several nights afterward.

A compound gone from the bloodstream in minutes shouldn’t, by conventional pharmacology, be shaping sleep hours later. This is the paradox no source in the research actually resolves.

What the research measured versus what it explains

In research settings, a sleep-pressure effect was observed roughly 130 minutes after a morning IV infusion, a fixed and reported figure. That’s a genuine data point, but it describes one protocol, one route (IV), one dose (25 nmol/kg), and one outcome measure.

It does not establish a general “kick in” time for DSIP under any other condition.

In commercial, subcutaneous-injection contexts, the “30 to 60 minutes before bed” instruction is an administration convention, not a demonstrated onset time. No source has measured when drowsiness or sleep-architecture change actually begins after a subcutaneous dose. It’s a scheduling habit borrowed from how sedatives are typically timed, not a finding specific to DSIP.

When to take it versus when it works

These are two different questions, and no source in the research answers both. “When to take it” is a dosing convention. “When it works,” if it works at all, appears to be decoupled from plasma presence entirely.

No standardized onset time exists across the sources reviewed here, and any single figure presented as universal should be treated skeptically.

An open mechanistic question, not an answer

The research raises, but does not confirm, one possible explanation: DSIP crosses the blood-brain barrier freely, so effects on CNS receptors could theoretically outlast how quickly the compound clears from plasma. That’s a reasonable hypothesis floated in the literature, not a demonstrated mechanism.

Until a receptor or binding site is identified, the gap between a 7-to-8-minute half-life and next-night sleep effects remains unexplained rather than solved.

Could DSIP Be a Natural Anesthetic?

One of the more unusual threads in DSIP’s research history has nothing to do with sleep aids or peptide-therapy protocols at all.

The European Journal of Anaesthesiology editorial, the single most authoritative source in this space, raises the question of whether DSIP interacts with GABA-A, glycine, or NMDA receptor sites, the same binding sites targeted by anaesthetic drugs used in surgical settings.

A question for anaesthesiologists, not a protocol for consumers

The editorial poses this explicitly as an open scientific question directed at anaesthesiology researchers, prompted by DSIP’s documented anticonvulsant activity against NMDA and picrotoxin challenge in animal studies and its ability to cross the blood-brain barrier freely.

It is not framed as a recommendation, a proposed treatment pathway, or evidence that DSIP produces sedation or anaesthesia in any tested human context.

Why this matters for readers

This angle belongs to the mechanism-unknown story, not the “does it help me sleep” story. No study has tested DSIP as a sedative or anaesthetic substitute, and nothing in the research supports using it as one.

The value here is intellectual: it shows how unresolved DSIP’s receptor pharmacology still is, decades after discovery, and why researchers continue to find it a genuinely open puzzle rather than a settled compound.

The History and Development of dsip peptide

From rabbit blood to a research chemical

DSIP’s origin story begins in 1977, when Swiss researchers Guido Schoenenberger (University of Basel) and M. Monnier (University of Zürich) isolated the peptide from the cerebral venous blood of rabbits during electrically-induced slow-wave sleep, publishing the characterization in PNAS.

That paper gave the field a specific sequence to work with, and the following two decades produced a steady stream of animal work and small human studies trying to figure out what the molecule actually did outside a rabbit’s bloodstream.

Graf and Kastin’s 1984 review in Neuroscience & Biobehavioral Reviews attempted to consolidate what was known by the mid-1980s, a sign that DSIP had moved from a single discovery into an active, if narrow, research niche.

Human data trickled in slowly: Bes and colleagues ran their double-blind insomnia trial in 1992, Friedman and colleagues studied DSIP’s diurnal rhythm and its behavior in Cushing’s syndrome in 1994, and Vgontzas and colleagues examined DSIP levels in sleep apnea and narcolepsy patients in 1995.

None of these produced the kind of large, replicated human trial base that would settle the mechanism debate discussed earlier in this article.

Academic interest thinned out after the 1990s, and DSIP’s afterlife has played out largely outside university labs. Today it circulates as a research-use-only compound sold by peptide vendors and, separately, as a compounded product marketed under the name “Emideltide.” The molecule’s science stalled in the lab decades ago, but its commercial life is still very much active.

Dosage and administration

DSIP shows up in two very different dosing worlds, and the research document doesn't connect them with any pharmacokinetic bridge. Treating them as interchangeable would misrepresent what's actually known.

The research-side dosing is weight-based and delivered directly into the bloodstream, calibrated to a specific nmol/kg figure used in the 1992 insomnia trial and related infusion studies.

The peptide-therapy figures come from clinic and vendor material describing flat microgram amounts injected subcutaneously, with no weight adjustment and no pharmacokinetic study connecting that dose to the IV research dose.

Nothing in the available sources translates one system into the other, so a 300 mcg subcutaneous dose cannot be assumed to approximate any fraction of a 25 nmol/kg infusion; the two numbers describe different delivery methods, different absorption pathways, and different eras of use.

Cycling patterns in the peptide-therapy context (commonly described as 2–4 weeks of use followed by a break) also have no established standard behind them; this is a convention reported in commercial and clinic material rather than a protocol validated by controlled research.

No FDA-approved dosing protocol exists for DSIP in any form. Where DSIP is used in real-world settings, whether through a compounding pharmacy or a wellness clinic, the protocol is provider-directed rather than standardized by regulatory guidance.

> A provider, not this article, determines any actual protocol.

Safety and side effects

What gets reported most often

Across the older research literature, the side effects tied directly to DSIP administration are consistently mild and limited to three: transient headache, nausea, and dizziness or vertigo. These appear in human trial contexts using intravenous dosing and are the only adverse effects with any real human data behind them.

Modern commercial sources selling DSIP for subcutaneous, at-home use also report injection-site reactions, redness, mild soreness, or irritation at the injection site, which is unsurprising for any self-administered peptide but has no formal human trial documentation behind it.

It should be read as a known category of risk for the delivery method itself, not something specifically studied for DSIP.

Animal toxicology: no LD50 ever established

In animal toxicology testing, researchers were unable to establish a lethal dose (LD50) for DSIP at any dose tested; animals could not be killed regardless of the amount given. This is a genuinely favorable safety signal, but it comes from animal studies only and says nothing about long-term effects of repeated dosing in humans.

Reported effects at a glance

What is theoretical, not demonstrated

Newer commercial and clinic-facing sources flag additional risks more cautiously: potential mood or neurotransmitter effects, dependency on DSIP for normal sleep cycling, and hormonal disruption. None of these are demonstrated in any trial; they are listed as theoretical considerations rather than confirmed outcomes, and should be weighed as such.

The bigger gap: no long-term human data

No source in the available research documents long-term human safety data for repeated or chronic DSIP use outside a supervised clinical trial setting. The 1992 insomnia trial ran over three nights under controlled conditions.

Claims of DSIP being “non-habit forming” or free of cumulative risk in ongoing, unsupervised use are not supported by any cited long-term study and should be treated as unverified.

Who should not use DSIP

Legal status

DSIP is not FDA-approved for any medical condition, and its legal status in the United States runs through the compounding pharmacy system rather than a standard drug approval pathway. That system changed twice in 2026, and both changes point in a more restrictive direction, though neither one closes the door completely.

What changed in 2026

According to a single source in our research base (Rite Aid), the FDA removed Emideltide/DSIP from the Section 503A Category 2 compounding list in April 2026.

Then, at a July 23-24, 2026 meeting, the FDA Pharmacy Compounding Advisory Committee considered adding DSIP to the Section 503A Bulks List for three potential uses: opioid withdrawal, chronic insomnia, and narcolepsy. The committee did not recommend the addition.

Why the Bulks List matters

In plain terms, the Bulks List is the roster of substances a compounding pharmacy can legally use to prepare a personalized medication when there's no FDA-approved commercial drug version.

A "yes" vote wouldn't have made DSIP an approved drug, but it would have given compounding pharmacies clearer legal footing to prepare it for patients under a practitioner's direction. A "no" recommendation keeps that pathway closed for now. Importantly, this vote was advisory only.

It does not represent a final FDA decision, and it does not, by itself, change what is currently allowed. Current access rules remain unchanged from before the vote.

Treat this as time-sensitive

This entire regulatory timeline, including both the April 2026 removal and the July 2026 advisory vote, comes from one source in the research used for this article. Regulatory status can shift quickly, committee recommendations can be revisited, and compounding rules vary by state as well as by federal list status.

Anyone making a decision based on DSIP's legal status should verify the current rules directly with the FDA or a compounding pharmacy rather than relying on a single dated snapshot.

The grey-market reality

Separate from the compounding pathway, DSIP is widely sold online by peptide vendors labeled "for research use only." That labeling puts these products in a different legal category entirely: they are not sold, marketed, or intended for human consumption, and they carry none of the oversight that applies to a prescribed or pharmacy-compounded product.

This research-use market exists regardless of what happens with the Bulks List decision, and it is not evidence of legal status for personal use.

Often used with

Comparators, not co-prescriptions Sleep-science literature discusses DSIP alongside melatonin, benzodiazepines, and z-drugs like zolpidem, but these appear as pharmacological comparison points for evaluating sleep-support approaches, not as agents studied in combination with DSIP. No research reviewed here tests DSIP taken together with any of these. Peptides named in the same commercial context Clinical/commercial peptide-therapy sources group DSIP alongside Epitalon, Semax, Selank, BPC-157, GH

Frequently asked questions